Breast Cancer
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02) OP-1250-302
- Details
ClinicalTrials.gov ID:
NCT07085767
Diagnosis Type:
NA
USOR Number:
- Address
,
P: